Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dronedarone in permanent atrial fibrillation with cardiovascular risk factors
2010-019791-73Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Dronedarone 400 mg BID + standard therapy with Placebo + standard therapy (2 arms). Primary endpoints: Composite major cardiovascular events and Unplanned cardiovascular hospitalization or death from any cause. Started Jun 2010; status: completed.
02
Drugs
dronedarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2010-019791-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019791-73.